Last reviewed · How we verify
Toradol
At a glance
| Generic name | Toradol |
|---|---|
| Also known as | ketorolac, periarticular injection, Multimodal Analgesia Protocol, Ketorolac, Sprix |
| Sponsor | The University of Texas Health Science Center, Houston |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Comparison of Pain Reduction in Painful Chronic Wounds With and Without Fat Grafting (NA)
- Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients (PHASE4)
- NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis (PHASE3)
- Ketorolac Intravenous Regional Analgesia in Lower Limb Surgeries (NA)
- Anesthetics and Analgesics in Children
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Toradol CI brief — competitive landscape report
- Toradol updates RSS · CI watch RSS
- The University of Texas Health Science Center, Houston portfolio CI